The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and ...
Image Source: Zacks Investment Research In our opinion, the deal is a strategic fit for Jazz Pharmaceuticals, which currently markets five oncology drugs, namely Defitelio, Vyxeos, Rylaze ...
The Business Research Company's Rylaze Global market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early ...
Oncology Revenue: Grew 9% in 2024 to over $1.1 billion. Rylaze Net Product Sales: $101 million in Q4 2024, $411 million for the full year, up 4% year-over-year. Zepzelca Net Product Sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback